Detalhe da pesquisa
1.
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
Blood
; 141(6): 567-578, 2023 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399715
2.
PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia.
Blood
; 139(9): 1340-1358, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34788382
3.
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Cancer
; 129(15): 2308-2320, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078412
4.
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Blood
; 137(13): 1792-1803, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024987
5.
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(5): 503-513, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37156478
6.
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Blood
; 135(7): 463-471, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31841594
7.
Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
Immunol Invest
; 51(8): 2176-2214, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36259611
8.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med
; 378(25): 2386-2398, 2018 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860938
9.
MRD in AML: who, what, when, where, and how?
Blood
; 143(4): 296-298, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38270942
10.
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
J Natl Compr Canc Netw
; 19(1): 16-27, 2021 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33406488
11.
Relapsed or primary refractory AML: moving past MEC and FLAG-ida.
Curr Opin Hematol
; 27(2): 108-114, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31904664
12.
Treating acute myeloid leukemia in the modern era: A primer.
Cancer
; 126(21): 4668-4677, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32767757
13.
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
Invest New Drugs
; 38(2): 340-349, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31102119
14.
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Am J Hematol
; 95(12): 1457-1465, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32777116
15.
Progress in the problem of relapsed or refractory acute myeloid leukemia.
Curr Opin Hematol
; 26(2): 88-95, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30640734
16.
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 17(6): 721-749, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31200351
17.
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors.
Haematologica
; 103(8): 1288-1297, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29773600
18.
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.
Haematologica
; 103(6): 982-987, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29567781
19.
Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients.
Hematol Oncol
; 40(1): 115-118, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34713477
20.
Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
Am J Hematol
; 96(7): E223-E225, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33761147